Table 1 Clinical features of patients recruited and the phenotype characterization of the xenografts obtained with cancer patients’ serum-treated cells
Cases | Tumor | Xenograft Phenotype (Pathology Report) | Differentiation Markers | Result |
|---|---|---|---|---|
Case219 Case100216 Case272 Case274 | CRC-LM CRC-LM CRC-LM CRC-LM | Convincing differentiation toward intestinal adenocarcinoma | CK7 CEA, CK20, CDX-2, and AE1/AE3 | Negative positive |
Case241 Case271 | HCC HCC | HCC differentiation is pretty convincing | AFP, CK8/18, and CEA Hep par-1 | positive negative |
Case290116 | PC | Differentiation toward typical pancreatic ductal adenocarcinoma | CK7, CK19, and AE1/AE3 | positive |
Case343 | OC | Ovarian cancer differentiation can be appreciated | Pax-8 CK20, WT-1, p53, and EMA | negative positive |
Case231Exo Case262Exo | CRC-LM CRC-LM | Convincing differentiation toward intestinal adenocarcinoma | CK7 CEA, CK20, CDX-2, and AE1/AE3 | negative positive |
Case348Exo Case247Exo | HCC HCC | HCC differentiation can be appreciated although Hep par-1 is negative | AFP, CK8/18, and CEA (canalicular pattern) Hep par-1 | positive negative |
Case290116Exo | PC | Differentiation toward typical pancreatic ductal adenocarcinoma | CK7, CK19, and AE1/AE3 | positive |
Case343Exo | OC | Ovarian cancer differentiation can be appreciated | Pax-8 CK20, WT-1, p53, and EMA | negative positive |